Effects on bone.
The actions of amylin on bone have been reviewed in several publications (MacIntyre, 1992a,b; MacIntyre et al., 1991; Reid and Cornish, 1996; Tamura et al., 1992a,b; Zaidi et al., 1990a,c, 1993b). MacIntyre proposed that amylin or its derivatives or agonists would be useful for treating bone disorders, such as osteoporosis, Paget's disease, or bone loss resulting from malignancy, endocrine disorders, autoimmune arthritides, breakage and fracture, immobility and disease, or hypercalcaemia (MacIntyre, 1995).
Amylin Pharmaceuticals, Inc., San Diego, California, USA.
Andrew
A
Young
D000682:Amyloid / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D001842:Bone and Bones / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D006801:Humans; D058228:Islet Amyloid Polypeptide; D010024:Osteoporosis / Q000188:drug therapy / Q000378:metabolism
D000682:Amyloid; D058228:Islet Amyloid Polypeptide